Experts worry insulin getting too expensive for many in U.S. and worldwide

Eric Palmer Healthcare professionals are concerned that hormone insulin meds, often the key diabetes treatment, are getting too costly for many patients, even in the U.S. In developing ...

FDA approves Lilly and Boehringer’s take on Sanofi’s top-selling insulin

Damian Garde Partners Eli Lilly and Boehringer Ingelheim inched closer to challenging Sanofi's best-selling insulin, winning FDA approval for their take on the blockbuster Lantus ...

Novo Nordisk strikes deal with Iran government to produce insulin pens in the country

Eric Palmer Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($ 78.1 million) plant to produce its FlexPen prefilled devices to better ...

Lilly’s new insulin is likely DOA after latest delay, analyst says

Damian Garde Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting ...

After multiple studies, MannKind finally wins an FDA OK for inhaled insulin Afrezza

John Carroll Three years and hundreds of millions of dollars after MannKind was handed its second FDA rejection on Afrezza, the third time proved the charm for the inhaled insulin. ...

Easing U.S. drug spending gives Sanofi, Novo room to raise insulin prices

Eric Palmer With generics flooding the market, U.S. drug spending fell by about 2% last year. That took pressure off of health insurers and left room for drug price hikes by those companies ...

Questions on MannKind’s inhaled insulin PhIII data cloud Afrezza’s future

John Carroll Early yesterday MannKind's Phase III data for Afrezza looked like a big hit with investors. But after a second look at the trial results, analysts' enthusiasm–and ...

MannKind touts good news from Afrezza inhaled insulin trial

Tracy Staton MannKind says it has gathered clearly positive late-stage data on its inhaled insulin Afrezza from a pair of Phase III studies on Type 1 and Type 2 diabetes. FiercePharma ...

U.K. pharma group’s cannabis-based diabetes drug sparks insulin output

Ryan McBride GW Pharmaceuticals has expanded mindsets about potential diabetes treatment. In a small midstage study of patients on its pot-based drug candidate, the U.K. drug developer ...

Oramed Enrolls First Patient in its Phase 2a U.S. Oral Insulin Clinical Trial

barbara.lempert Marks initiation of Oramed’s first FDA trial for its flagship ORMD-0801 oral insulin product JERUSALEM, July 8, 2013 /PRNewswire/ — Oramed Pharmaceuticals ...

Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541

barbara.lempert Data to be Presented at the 73rd American Diabetes Association Scientific Sessions® Further Explore Mealtime Insulin Requirements in Patients with Type 1 Diabetes CHICAGO, ...

Phase III data show investigational compound empagliflozin plus insulin significantly reduced HbA1c

barbara.lempert Phase III data show investigational compound empagliflozin plus insulin significantly reduced HbA1c in adults with type 2 diabetes Data presented at the American Diabetes ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS